Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
probiotic i3.1 + prebiotic ProSeed
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A synbiotic combination consisting of the i3.1 probiotic blend and the ProSeed prebiotic fiber. The i3.1 component is a specific mixture of three bacterial strains: *Lactobacillus plantarum* CECT 7484, *Lactobacillus plantarum* CECT 7485, and *Pediococcus acidilactici* CECT 7483. The ProSeed component consists of partially hydrolyzed guar gum (PHGG), a soluble prebiotic fiber. This combination is primarily indicated for the management of Irritable Bowel Syndrome (IBS), where it acts by modulating the intestinal microbiota, improving stool consistency, and reducing visceral hypersensitivity and intestinal inflammation. The probiotic strains were selected for their high adherence to the intestinal epithelium and their ability to produce short-chain fatty acids, which support gut barrier function.
- Brand names
- i3.1i-3.1i 3.1ProSeed
- Other names
- i3.1 + ProSeedAB-Biotics i3.1Synbiotic i3.1 + ProSeed
Beyond the preview
Go deeper on probiotic i3.1 + prebiotic ProSeed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on probiotic i3.1 + prebiotic ProSeed.